UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 57

Sortiert nach

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

Thorax, 2003-05, Vol.58 (5), p.399-404

2003

Volltextzugriff (PDF)

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

The European respiratory journal, 2002-02, Vol.19 (2), p.209-216

2002

Volltextzugriff (PDF)

A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease

Thorax, 2000-04, Vol.55 (4), p.289-294

2000

Volltextzugriff (PDF)

L’association fixe tiotropium + olodatérol Respimat® a un délai d’action rapide chez les patients BPCO

Revue des maladies respiratoires, 2016-01, Vol.33, p.A197-A197

2016

Volltextzugriff (PDF)

Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease

The European respiratory journal, 2002-04, Vol.19 (4), p.639-644

2002

Volltextzugriff (PDF)

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

Annals of internal medicine, 2005-09, Vol.143 (5), p.317

2005

Volltextzugriff (PDF)

Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

Thorax, 2006-01, Vol.61 (1), p.91-91

2006

Volltextzugriff (PDF)

L’administration une fois par jour d’une association fixe de tiotropium et d’olodatérol par Respimat a amélioré les résultats par rapport aux composants individuels dans les BPCO au cours de deux études d’un an

Revue des maladies respiratoires, 2015-01, Vol.32, p.A77-A77

2015

Volltextzugriff (PDF)

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies

International journal of chronic obstructive pulmonary disease, 2014-01, Vol.9 (default), p.697-714

2014

Volltextzugriff (PDF)

P128 Pooled safety analysis of adjudicated serious adverse events with the combination of tiotropium + olodaterol

Thorax, 2015-12, Vol.70 (Suppl 3), p.A140

2015

Volltextzugriff (PDF)

P128 Pooled safety analysis of adjudicated serious adverse events with the combination of tiotropium + olodaterol: Abstract P128 Table 1

Thorax, 2015-12, Vol.70 (Suppl 3), p.A140-A141

2015

Volltextzugriff (PDF)

D36 ALL TOGETHER NOW: COPD TREATMENT WITH LONG-ACTING BETA AGONISTS AND LONG-ACTING MUSCARINIC ANTAGONISTS: Pooled Safety Analysis Of Adjudicated Serious Adverse Events With The Fixed-Dose Combination Of Tiotropium + Olodaterol

American journal of respiratory and critical care medicine, 2015-01, Vol.191, p.1

2015

Volltextzugriff (PDF)

Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies

International journal of chronic obstructive pulmonary disease, 2014-01, Vol.9 (default), p.629-645

2014

Volltextzugriff (PDF)

P121 Characteristics of COPD patients with and without maintenance treatment at baseline, by GOLD stage: TONADO: Abstract P121 Table 1

Thorax, 2015-12, Vol.70 (Suppl 3), p.A135-A136

2015

Volltextzugriff (PDF)

P125 Tiotropium plus olodaterol combination therapy provides lung-function benefits when compared to tiotropium alone, irrespective of prior treatment with a long-acting bronchodilator: post hoc analyses of two 1-year studies

Thorax, 2015-12, Vol.70 (Suppl 3), p.A138

2015

Volltextzugriff (PDF)

P121 Characteristics of COPD patients with and without maintenance treatment at baseline, by GOLD stage: TONADO

Thorax, 2015-12, Vol.70 (Suppl 3), p.A135

2015

Volltextzugriff (PDF)

P125 Tiotropium plus olodaterol combination therapy provides lung-function benefits when compared to tiotropium alone, irrespective of prior treatment with a long-acting bronchodilator: post hoc analyses of two 1-year studies: Abstract P125 Table 1

Thorax, 2015-12, Vol.70 (Suppl 3), p.A138-A139

2015

Volltextzugriff (PDF)

D36 ALL TOGETHER NOW: COPD TREATMENT WITH LONG-ACTING BETA AGONISTS AND LONG-ACTING MUSCARINIC ANTAGONISTS: Analysis Of The Efficacy And Safety Of The Fixed-Dose Combination Of Tiotropium + Olodaterol In Patients With COPD By Initial Disease Severity

American journal of respiratory and critical care medicine, 2015-01, Vol.191, p.1

2015

Volltextzugriff (PDF)

D36 ALL TOGETHER NOW: COPD TREATMENT WITH LONG-ACTING BETA AGONISTS AND LONG-ACTING MUSCARINIC ANTAGONISTS: Tiotropium Plus Olodaterol Fixed-Dose Combination Therapy Provides Lung Function Benefits When Compared With Tiotropium Alone, Irrespective Of Prior Treatment With A Long-Acting Bronchodilator: Post Hoc Analyses Of Two 1-Year Studies

American journal of respiratory and critical care medicine, 2015-01, Vol.191, p.1

2015

Volltextzugriff (PDF)

D36 ALL TOGETHER NOW: COPD TREATMENT WITH LONG-ACTING BETA AGONISTS AND LONG-ACTING MUSCARINIC ANTAGONISTS: Characteristics Of COPD Patients With And Without Maintenance Treatment At Baseline, By Gold Stage: Tonado

American journal of respiratory and critical care medicine, 2015-01, Vol.191, p.1

2015

Volltextzugriff (PDF)

D36 ALL TOGETHER NOW: COPD TREATMENT WITH LONG-ACTING BETA AGONISTS AND LONG-ACTING MUSCARINIC ANTAGONISTS: Analysis Of The Efficacy And Safety Of The Fixed-Dose Combination Of Tiotropium + Olodaterol In Patients With COPD By Previous Usage Of Inhaled Corticosteroids

American journal of respiratory and critical care medicine, 2015-01, Vol.191, p.1

2015

Volltextzugriff (PDF)

S61 Analysis of the efficacy and safety of the combination of tiotropium + olodaterol in patients with COPD by previous usage of inhaled corticosteroids

Thorax, 2015-12, Vol.70 (Suppl 3), p.A37

2015

Volltextzugriff (PDF)

S61 Analysis of the efficacy and safety of the combination of tiotropium + olodaterol in patients with COPD by previous usage of inhaled corticosteroids: Abstract S61 Table 1

Thorax, 2015-12, Vol.70 (Suppl 3), p.A37-A37

2015

Volltextzugriff (PDF)

S34 Effect of 8 and 12 weeks’ once-daily tiotropium and olodaterol, alone and combined with exercise training, on exercise endurance during walking in patients with copd

Thorax, 2016-12, Vol.71 (Suppl 3), p.A21-A22

2016

Volltextzugriff (PDF)

S34Effect of 8 and 12 weeks' once-daily tiotropium and olodaterol, alone and combined with exercise training, on exercise endurance during walking in patients with copd

Thorax, 2016-12, Vol.71 (Suppl 3), p.A21-A22

2016

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(57)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(25)
Science & Technology
(25)
Female
(18)
Biological And Medical Sciences
(16)
Male
(16)
Humans
(14)
Animals
(12)
Physiology
(12)
Sport Sciences
(11)
Chronic Obstructive Pulmonary Disease
(10)
Medical Sciences
(10)
Respiratory System
(10)
Blood Gas Analysis
(9)
Middle Aged
(9)
Pulmonary Disease, Chronic Obstructive - Drug Therapy
(9)
Administration, Inhalation
(8)
Bronchodilator Agents - Administration & Dosage
(8)
Double-Blind Method
(8)
Respiratory Mechanics - Physiology
(8)
Asthma
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease

L’association fixe tiotropium + olodatérol Respimat® a un délai d’action rapide chez les patients BPCO

Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

L’administration une fois par jour d’une association fixe de tiotropium et d’olodatérol par Respimat a amélioré les résultats par rapport aux composants individuels dans les BPCO au cours de deux études d’un an

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies

P128 Pooled safety analysis of adjudicated serious adverse events with the combination of tiotropium + olodaterol

P128 Pooled safety analysis of adjudicated serious adverse events with the combination of tiotropium + olodaterol: Abstract P128 Table 1

D36 ALL TOGETHER NOW: COPD TREATMENT WITH LONG-ACTING BETA AGONISTS AND LONG-ACTING MUSCARINIC ANTAGONISTS: Pooled Safety Analysis Of Adjudicated Serious Adverse Events With The Fixed-Dose Combination Of Tiotropium + Olodaterol

Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies

P121 Characteristics of COPD patients with and without maintenance treatment at baseline, by GOLD stage: TONADO: Abstract P121 Table 1

P125 Tiotropium plus olodaterol combination therapy provides lung-function benefits when compared to tiotropium alone, irrespective of prior treatment with a long-acting bronchodilator: post hoc analyses of two 1-year studies

P121 Characteristics of COPD patients with and without maintenance treatment at baseline, by GOLD stage: TONADO

P125 Tiotropium plus olodaterol combination therapy provides lung-function benefits when compared to tiotropium alone, irrespective of prior treatment with a long-acting bronchodilator: post hoc analyses of two 1-year studies: Abstract P125 Table 1

D36 ALL TOGETHER NOW: COPD TREATMENT WITH LONG-ACTING BETA AGONISTS AND LONG-ACTING MUSCARINIC ANTAGONISTS: Analysis Of The Efficacy And Safety Of The Fixed-Dose Combination Of Tiotropium + Olodaterol In Patients With COPD By Initial Disease Severity

D36 ALL TOGETHER NOW: COPD TREATMENT WITH LONG-ACTING BETA AGONISTS AND LONG-ACTING MUSCARINIC ANTAGONISTS: Characteristics Of COPD Patients With And Without Maintenance Treatment At Baseline, By Gold Stage: Tonado

D36 ALL TOGETHER NOW: COPD TREATMENT WITH LONG-ACTING BETA AGONISTS AND LONG-ACTING MUSCARINIC ANTAGONISTS: Analysis Of The Efficacy And Safety Of The Fixed-Dose Combination Of Tiotropium + Olodaterol In Patients With COPD By Previous Usage Of Inhaled Corticosteroids

S61 Analysis of the efficacy and safety of the combination of tiotropium + olodaterol in patients with COPD by previous usage of inhaled corticosteroids

S61 Analysis of the efficacy and safety of the combination of tiotropium + olodaterol in patients with COPD by previous usage of inhaled corticosteroids: Abstract S61 Table 1

S34 Effect of 8 and 12 weeks’ once-daily tiotropium and olodaterol, alone and combined with exercise training, on exercise endurance during walking in patients with copd

S34Effect of 8 and 12 weeks' once-daily tiotropium and olodaterol, alone and combined with exercise training, on exercise endurance during walking in patients with copd

Suchergebnisse filtern